(sodium polystyrene sulfonate) Powder for Suspension
KAYEXALATE is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:
The drug is a cream to light brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq (in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or rectally as an enema.
One gram of KAYEXALATE contains 4.1 mEq of sodium.
KAYEXALATE is indicated for the treatment of hyperkalemia.
Limitation Of Use
KAYEXALATE should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see CLINICAL PHARMACOLOGY].
DOSAGE AND ADMINISTRATION
The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.
The average total daily adult dose of KAYEXALATE is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily.
The average adult dose is 30 g to 50 g every six hours.
Preparation And Administration
Prepare suspension fresh and use within 24 hours.
Do not heat KAYEXALATE as it could alter the exchange properties of the resin.
One level teaspoon contains approximately 3.5 g of KAYEXALATE and 15 mEq of sodium.
Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste.
Agitate the emulsion gently during administration. The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized.
Dosage Forms And Strengths
KAYEXALATE is a cream to light brown, finely ground powder and is available in 453.6 g jars.
Storage And Handling
KAYEXALATE is available as a cream to light brown, finely ground powder in jars of 1 pound (453.6 g), NDC 59212-075-01.
Store at 25° C (77° F); excursions permitted to 15° – 30° C (59° – 86° F) [see USP Controlled Room Temperature]
Manufactured for: Concordia Pharmaceutical Inc. St. Michael, Barbados BB11005. Revised Jul 2017
The following adverse reactions are discussed elsewhere in the labeling:
- Intestinal Necrosis [see WARNINGS AND PRECAUTIONS]
- Electrolyte Disturbances [see WARNINGS AND PRECAUTIONS]
- Aspiration [see WARNINGS AND PRECAUTIONS]
The following adverse reactions have been identified during post-approval use of KAYEXALATE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.
Gastrointestinal: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide)
Metabolic: systemic alkalosis
No formal drug interaction studies have been conducted in humans.
KAYEXALATE has the potential to bind other drugs. In in vitro binding studies, KAYEXALATE was shown to significantly bind the oral medications (n=6) that were tested. Decreased absorption of lithium and thyroxine have also been reported with co-administration of KAYEXALATE. Binding of KAYEXALATE to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time KAYEXALATE is administered. Administer KAYEXALATE at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation. Monitor for clinical response and/or blood levels where possible.
The simultaneous oral administration of KAYEXALATE with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis.
Sorbitol may contribute to the risk of intestinal necrosis [see WARNINGS AND PRECAUTIONS] and concomitant use is not recommended.
Included as part of the PRECAUTIONS section.
Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with KAYEXALATE use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended.
- Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.
- Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction). Discontinue use in patients who develop constipation.
KAYEXALATE is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving KAYEXALATE.
Fluid Overload In Patients Sensitive To High Sodium Intake
Each 15 g dose of KAYEXALATE contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload. Adjustment of other sources of sodium may be required.
Risk Of Aspiration
Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported. Patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk. Administer KAYEXALATE with the patient in an upright position.
Binding To Other Orally Administered Medications
KAYEXALATE may bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy. Administer other oral medications at least 3 hours before or 3 hours after KAYEXALATE. Patients with gastroparesis may require a 6 hour separation. [see DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS].
Carcinogenesis, Mutagenesis, Impairment Of Fertility
Studies have not been performed.
Use In Specific Populations
KAYEXALATE is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk.
KAYEXALATE is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant.
Studies of safety and efficacy have not been conducted in pediatric patients.
In pediatric patients, as in adults, KAYEXALATE is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin.
In neonates, KAYEXALATE should not be given by the oral route. In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with KAYEXALATE. use [see WARNINGS AND PRECAUTIONS].
Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.
KAYEXALATE is contraindicated in patients with the following conditions:
- Hypersensitivity to polystyrene sulfonate resins
- Obstructive bowel disease
- Neonates with reduced gut motility
Mechanism Of Action
KAYEXALATE is a non-absorbed, cation exchange polymer that contains a sodium counterion.
KAYEXALATE increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.
As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable.
The effective lowering of serum potassium with KAYEXALATE may take hours to days.
The in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body.
KAYEXALATE is not absorbed systemically.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.